Intranasal ipratropium in the treatment of vasomotor rhinitis.
Ipratropium administered in the form of a nasal spray was compared with placebo in 30 patients with vasomotor rhinitis in a double-blind cross-over trial. There was a significant reduction in nasal hypersecretion during ipratropium treatment, but no effect on nasal blockage, sneezing or tickling. On the whole, 20 patients (66.7%) considered ipratropium worth using. 11 patients had mild side- effects, mainly nasal irritation, during ipratropium treatment and 7 with placebo. A therapeutical trial with ipratropium is appropriate in the management of severe rhinorrhoea in patients with vasomotor rhinitis.